Siglecs as targets for therapy in immune-cell-mediated disease

Trends in Pharmacological Sciences

Volumn 30, Issue 5, 2009, Pages 240-248

  O'Reilly, Mary K ^a   Paulson, James C ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BL 22; EPRATUZUMAB; GEMTUZUMAB OZOGAMICIN; INOTUZUMAB OZOGAMICIN; LECTIN; METHOTREXATE; RITUXIMAB; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN DERIVATIVE; SIALIC ACID DERIVATIVE; SIALOADHESIN; SIGLEC 2; SIGLEC 3; SIGLEC 8; SIGLEC 9; SIGLEC DERIVATIVE; UNCLASSIFIED DRUG; VELTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; APOPTOSIS; AUTOIMMUNE DISEASE; BONE MARROW CELL; CELL THERAPY; CELLULAR IMMUNODEFICIENCY; DRUG TARGETING; EOSINOPHIL; HAIRY CELL LEUKEMIA; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VIVO STUDY; LYMPHOID CELL; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; RHEUMATOID ARTHRITIS;

AMINOGLYCOSIDES; ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD22; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNE SYSTEM DISEASES; LECTINS; LEUKEMIA; LYMPHOCYTE DEPLETION; LYMPHOMA, B-CELL; MODELS, BIOLOGICAL; POLYSACCHARIDES;

EID: 65349147691     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2009.02.005     Document Type: Review

References (104)

1. Ball E.D. In vitro purging of bone marrow for autologous marrow transplantation in acute myelogenous leukemia using myeloid-specific monoclonal antibodies. Bone Marrow Transplant. 3 (1988) 387-392
2. Drexler H.G. Classification of acute myeloid leukemias-a comparison of FAB and immunophenotyping. Leukemia 1 (1987) 697-705
3. Chen Z., et al. Immunological typing of acute lymphoblastic leukemia: concurrent analysis by flow cytofluorometry and immunocytology. Leuk. Res. 10 (1986) 1411-1417
4. Mason D.Y., et al. Value of monoclonal anti-CD22 (p135) antibodies for the detection of normal and neoplastic B lymphoid cells. Blood 69 (1987) 836-840
5. May R.D., et al. Selective killing of normal and neoplastic human B cells with anti-CD19- and anti-CD22-ricin A chain immunotoxins. Cancer Drug Deliv. 3 (1986) 261-272
6. Ziegler-Heitbrock H.W., et al. Induction of features characteristic of hairy cell leukemia in chronic lymphocytic leukemia and prolymphocytic leukemia cells. Cancer Res. 46 (1986) 2172-2178
7. Freeman S.D., et al. Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 85 (1995) 2005-2012
8. Kelm S., et al. Sialoadhesin, myelin-associated glycoprotein and CD22 define a new family of sialic acid-dependent adhesion molecules of the immunoglobulin superfamily. Curr. Biol. 4 (1994) 965-972
9. Sgroi D., et al. CD22, a B cell-specific immunoglobulin superfamily member, is a sialic acid-binding lectin. J. Biol. Chem. 268 (1993) 7011-7018
10. Cao H., et al. SIGLEC16 encodes a DAP12-associated receptor expressed in macrophages that evolved from its inhibitory counterpart SIGLEC11 and has functional and non-functional alleles in humans. Eur. J. Immunol. 38 (2008) 2303-2315
11. Crocker P.R., et al. Siglecs and their roles in the immune system. Nat. Rev. Immunol. 7 (2007) 255-266
12. Crocker P.R., and Redelinghuys P. Siglecs as positive and negative regulators of the immune system. Biochem. Soc. Trans. 36 (2008) 1467-1471
13. von Gunten S., and Bochner B.S. Basic and clinical immunology of Siglecs. Ann. N. Y. Acad. Sci. 1143 (2008) 61-82
14. Walker J.A., and Smith K.G. CD22: an inhibitory enigma. Immunology 123 (2008) 314-325
15. Tedder T.F., et al. CD22: A multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv. Immunol. 88 (2005) 1-50
16. Collins B.E., et al. Ablation of CD22 in ligand-deficient mice restores B cell receptor signaling. Nat. Immunol. 7 (2006) 199-206
17. Grewal P.K., et al. ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling. Mol. Cell. Biol. 26 (2006) 4970-4981
18. John B., et al. The B cell coreceptor CD22 associates with AP50, a clathrin-coated pit adapter protein, via tyrosine-dependent interaction. J. Immunol. 170 (2003) 3534-3543
19. Shan D., and Press O.W. Constitutive endocytosis and degradation of CD22 by human B cells. J. Immunol. 154 (1995) 4466-4475
20. Tateno H., et al. Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity. Mol. Cell. Biol. 27 (2007) 5699-5710
21. Stoddart A., et al. Lipid rafts unite signaling cascades with clathrin to regulate BCR internalization. Immunity 17 (2002) 451-462
22. Stoddart A., et al. Plasticity of B cell receptor internalization upon conditional depletion of clathrin. Mol. Biol. Cell 16 (2005) 2339-2348
23. Jones C., et al. Recognition of sialylated meningococcal lipopolysaccharide by siglecs expressed on myeloid cells leads to enhanced bacterial uptake. Mol. Microbiol. 49 (2003) 1213-1225
24. Rempel H., et al. Sialoadhesin expressed on IFN-induced monocytes binds HIV-1 and enhances infectivity. PLoS ONE 3 (2008) e1967
25. Vanderheijden N., et al. Involvement of sialoadhesin in entry of porcine reproductive and respiratory syndrome virus into porcine alveolar macrophages. J. Virol. 77 (2003) 8207-8215
26. Biedermann B., et al. Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitors. Leuk. Res. 31 (2007) 211-220
27. Walter R.B., et al. ITIM-dependent endocytosis of CD33-related Siglecs: role of intracellular domain, tyrosine phosphorylation, and the tyrosine phosphatases, Shp1 and Shp2. J. Leukoc. Biol 83 (2008) 200-211
28. Walter R.B., et al. Phosphorylated ITIMs enable ubiquitylation of an inhibitory cell surface receptor. Traffic 9 (2008) 267-279
29. Zhang J., et al. Characterization of Siglec-H as a novel endocytic receptor expressed on murine plasmacytoid dendritic cell precursors. Blood 107 (2006) 3600-3608
30. Bregni M., et al. B-cell restricted saporin immunotoxins: activity against B-cell lines and chronic lymphocytic leukemia cells. Blood 73 (1989) 753-762
31. Ghetie M.A., et al. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Cancer Res. 48 (1988) 2610-2617
32. Audran R., et al. Internalization of human macrophage surface antigens induced by monoclonal antibodies. J. Immunol. Methods 188 (1995) 147-154
33. Engert A., et al. Resistance of myeloid leukaemia cell lines to ricin A-chain immunotoxins. Leuk. Res. 15 (1991) 1079-1086
34. Press O.W., et al. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res. 49 (1989) 4906-4912
35. van Der Velden V.H., et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97 (2001) 3197-3204
36. Bross P.F., et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7 (2001) 1490-1496
37. Pagano L., et al. The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients. Oncogene 26 (2007) 3679-3690
38. Walter R.B., et al. Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts. Blood 111 (2008) 4813-4816
39. La Russa V.F., et al. Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures. Exp. Hematol. 20 (1992) 442-448
40. Scott C.J., et al. Immunocolloidal targeting of the endocytotic siglec-7 receptor using peripheral attachment of siglec-7 antibodies to poly(lactide-co-glycolide) nanoparticles. Pharm. Res. 25 (2008) 135-146
41. Biagi E., et al. Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies. Haematologica 92 (2007) 381-388
42. Davis T.A., et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol. 18 (2000) 3135-3143
43. Feuring-Buske M., et al. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann. Hematol. 79 (2000) 493-500
44. Foran J.M., et al. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br. J. Haematol. 109 (2000) 81-88
45. McLaughlin P., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16 (1998) 2825-2833
46. Kreitman R.J., et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 345 (2001) 241-247
47. Du X., et al. Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res. 68 (2008) 6300-6305
48. DiJoseph J.F., et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin. Cancer Res. 12 (2006) 242-249
49. DiJoseph J.F., et al. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. Cancer Immunol. Immunother. 54 (2005) 11-24
50. Dijoseph J.F., et al. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 21 (2007) 2240-2245
51. Castillo J., et al. Newer monoclonal antibodies for hematological malignancies. Exp. Hematol. 36 (2008) 755-768
52. Leonard J.P., et al. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 113 (2008) 2714-2723
53. Mattes M.J., et al. Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab). Clin. Cancer Res. 14 (2008) 6154-6160
54. Leonard J.P., and Link B.K. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Semin. Oncol. 29 (2002) 81-86
55. Jacobi A.M., et al. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann. Rheum. Dis. 67 (2008) 450-457
56. Qu Z., et al. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood 111 (2008) 2211-2219
57. Haas K.M., et al. CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo. J. Immunol. 177 (2006) 3063-3073
58. Levesque M.C., and St Clair E.W. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J. Allergy Clin. Immunol. 121 (2008) 13-21
59. Silverman G.J., and Boyle D.L. Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B-cell roadblock hypothesis. Immunol. Rev. 223 (2008) 175-185
60. Matthews R. Autoimmune diseases. The B cell slayer. Science 318 (2007) 1232-1233
61. Lopez-Diego R.S., and Weiner H.L. Novel therapeutic strategies for multiple sclerosis - a multifaceted adversary. Nat. Rev. Drug Discov. 7 (2008) 909-925
62. Bochner B.S., et al. Glycan array screening reveals a candidate ligand for Siglec-8. J. Biol. Chem. 280 (2005) 4307-4312
63. Tateno H., et al. Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 6'-sulfo-sialyl Lewis X as a preferred glycan ligand. Glycobiology 15 (2005) 1125-1135
64. Zhang M., et al. Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils. Blood 109 (2007) 4280-4287
65. Nutku E., et al. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 101 (2003) 5014-5020
66. Zimmermann N., et al. Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils. Allergy 63 (2008) 1156-1163
67. Song, D.J. et al. Anti-Siglec-F antibody inhibits oral egg allergen induced intestinal eosinophilic inflammation in a mouse model. Clin. Immunol. DOI:10.1016/j.clim.2008.11.009. (www.sciencedirect.com)
68. von Gunten S., et al. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J. Allergy Clin. Immunol. 119 (2007) 1005-1011
69. Yokoi H., et al. Inhibition of FcεRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement. J. Allergy Clin. Immunol. 121 (2008) 499-505.e1
70. Hartnell A., et al. Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations. Blood 97 (2001) 288-296
71. van der Kuyl A.C., et al. Sialoadhesin (CD169) expression in CD14+ cells is upregulated early after HIV-1 infection and increases during disease progression. PLoS One 2 (2007) e257
72. Kim S., et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457 (2009) 102-106
73. Revilla C., et al. Targeting to porcine sialoadhesin receptor improves antigen presentation to T cells. Vet. Res. 40 (2008) 14
74. von Gunten S., and Simon H.U. Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg). Autoimmun. Rev. 7 (2008) 453-456
75. von Gunten S., et al. Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment. Blood 106 (2005) 1423-1431
76. von Gunten S., et al. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood 108 (2006) 4255-4259
77. Razi N., and Varki A. Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 7469-7474
78. Crocker P.R., and Varki A. Siglecs, sialic acids and innate immunity. Trends Immunol. 22 (2001) 337-342
79. Abdu-Allah H.H., et al. Design, synthesis, and structure-affinity relationships of novel series of sialosides as CD22-specific inhibitors. J. Med. Chem. 51 (2008) 6665-6681
80. Collins B.E., et al. High-affinity ligand probes of CD22 overcome the threshold set by cis ligands to allow for binding, endocytosis, and killing of B cells. J. Immunol. 177 (2006) 2994-3003
81. Kaltgrad E., et al. On-virus construction of polyvalent glycan ligands for cell-surface receptors. J. Am. Chem. Soc. 130 (2008) 4578-4579
82. Kelm S., et al. The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound. J. Exp. Med. 195 (2002) 1207-1213
83. O'Reilly M.K., et al. Bifunctional CD22 ligands use multimeric immunoglobulins as protein scaffolds in assembly of immune complexes on B cells. J. Am. Chem. Soc. 130 (2008) 7736-7745
84. Hattori Y., et al. Efficient gene transfer into macrophages and dendritic cells by in vivo gene delivery with mannosylated lipoplex via the intraperitoneal route. J. Pharmacol. Exp. Ther. 318 (2006) 828-834
85. Ikehara Y., and Kojima N. Development of a novel oligomannose-coated liposome-based anticancer drug-delivery system for intraperitoneal cancer. Curr. Opin. Mol. Ther. 9 (2007) 53-61
86. Irache J.M., et al. Mannose-targeted systems for the delivery of therapeutics. Expert Opin. Drug Deliv. 5 (2008) 703-724
87. Kuramoto Y., et al. Use of mannosylated cationic liposomes/immunostimulatory CpG DNA complex for effective inhibition of peritoneal dissemination in mice. J. Gene Med. 10 (2008) 392-399
88. Arakawa Y., et al. Eye-concentrated distribution of dexamethasone carried by sugar-chain modified liposome in experimental autoimmune uveoretinitis mice. Biomed. Res. 28 (2007) 331-334
89. Hashida N., et al. High-efficacy site-directed drug delivery system using sialyl-Lewis X conjugated liposome. Exp. Eye Res. 86 (2008) 138-149
90. Hirai M., et al. Accumulation of liposome with Sialyl Lewis X to inflammation and tumor region: application to in vivo bio-imaging. Biochem. Biophys. Res. Commun. 353 (2007) 553-558
91. Tsuruta W., et al. Application of liposomes incorporating doxorubicin with sialyl Lewis X to prevent stenosis after rat carotid artery injury. Biomaterials 30 (2009) 118-125
92. Monteiro V.G., et al. Increased association of Trypanosoma cruzi with sialoadhesin positive mice macrophages. Parasitol. Res. 97 (2005) 380-385
93. Blixt O., et al. Sialoside specificity of the siglec family assessed using novel multivalent probes: identification of potent inhibitors of myelin-associated glycoprotein. J. Biol. Chem. 278 (2003) 31007-31019
94. Brinkman-Van der Linden E.C., and Varki A. New aspects of siglec binding specificities, including the significance of fucosylation and of the sialyl-Tn epitope. Sialic acid-binding immunoglobulin superfamily lectins. J. Biol. Chem 275 (2000) 8625-8632
95. Kimura N., et al. Human B-lymphocytes express α2-6-sialylated 6-sulfo-N-acetyllactosamine serving as a preferred ligand for CD22/Siglec-2. J. Biol. Chem. 282 (2007) 32200-32207
96. Terstappen L.W., et al. Quantitative comparison of myeloid antigens on five lineages of mature peripheral blood cells. J. Leukoc. Biol. 48 (1990) 138-148
97. Yokoi H., et al. Alteration and acquisition of Siglecs during in vitro maturation of CD34+ progenitors into human mast cells. Allergy 61 (2006) 769-776
98. Pedraza L., et al. Differential expression of MAG isoforms during development. J. Neurosci. Res. 29 (1991) 141-148
99. Angata T., et al. Discovery of Siglec-14, a novel sialic acid receptor undergoing concerted evolution with Siglec-5 in primates. FASEB J. 20 (2006) 1964-1973
100. Brinkman-Van der Linden E.C., et al. Human-specific expression of Siglec-6 in the placenta. Glycobiology 17 (2007) 922-931
101. Avril T., et al. Sialic acid-binding immunoglobulin-like lectin 7 mediates selective recognition of sialylated glycans expressed on Campylobacter jejuni lipooligosaccharides. Infect. Immun. 74 (2006) 4133-4141
102. Munday J., et al. Identification, characterization and leucocyte expression of Siglec-10, a novel human sialic acid-binding receptor. Biochem. J. 355 (2001) 489-497
103. Angata T., et al. Cloning and characterization of human Siglec-11. A recently evolved signaling that can interact with SHP-1 and SHP-2 and is expressed by tissue macrophages, including brain microglia. J. Biol. Chem. 277 (2002) 24466-24474
104. Angata T., et al. Siglec-15: an immune system Siglec conserved throughout vertebrate evolution. Glycobiology 17 (2007) 838-846